Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1558 in Healthy Adult Volunteers

Daewoong Pharmaceutical

Status and phase: Active, not recruiting; Phase 1

Conditions: Healthy Volunteers

Treatments: Drug: DWC202310 and DWC202311; Drug: DWJ1558

Study type: Interventional

Funder types: Industry

Identifiers

NCT06010589

DWJ1558101

Details and patient eligibility

About

This study aims to compare the pharmacokinetics and safety following administration of DWJ1558 and co-administration of DWC202310 and DWC202311 in healthy volunteers.

Enrollment: 66 patients

Sex: All

Ages: 19+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• over 19 year old

Exclusion criteria

• Pancreatitis
• Diabetic ketoacidosis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

66 participants in 2 patient groups

Intervention: DWJ1558

Experimental group

Treatment:

Drug: DWJ1558

Intervention: DWC202310 and DWC202311

Experimental group

Treatment:

Drug: DWC202310 and DWC202311